Atrasentan in Treating Patients With Prostate Cancer

Abbott

Overview

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.

OBJECTIVES: * Determine the safety of atrasentan in patients with hormone-refractory prostate cancer. * Determine the pharmacokinetics of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral atrasentan once daily for 3 years in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month and then every 3 months for 2 years. PROJECTED ACCRUAL: Approximately 1,400 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Conditions

Prostate Cancer

Interventions

atrasentan hydrochlorideDRUG

Eligibility

Sex: MALEMin age: 19 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of hormone-refractory prostate cancer * Completed protocol ABBOTT-M00-211 or ABBOTT-M00-244 within the past 30 days * Disease progression OR * Active in trial when double-blind treatment period ended PATIENT CHARACTERISTICS: Age * 19 and over Performance status * Karnofsky 60-100% Life expectancy * Not specified Hematopoietic * WBC at least 3,000/mm3 * Absolute neutrophil count greater than 1,000/mm3 * Platelet count at least 100,000/mm3 * Hemoglobin at least 9 g/dL Hepatic * Bilirubin less than 1.5 mg/dL * AST and ALT no greater than 1.5 times upper limit of normal Renal * Creatinine clearance at least 40 mL/min Cardiovascular * No New York Heart Association class II-IV heart disease Pulmonary * No significant pulmonary disease requiring chronic or pulse steroid therapy within the past 3 months Other * Fertile patients must use 2 effective methods of contraception (1 must be barrier contraception) during and for 8 weeks after study * No reason that would preclude study * No significant comorbid condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * At least 4 weeks since other prior cytotoxic chemotherapy * No other concurrent cytotoxic chemotherapy Endocrine therapy * Not specified Radiotherapy * At least 4 weeks since prior radionuclides * No concurrent radionuclides Surgery * Not specified Other * At least 4 weeks since prior investigational agents * No concurrent antiretroviral therapy for HIV-positive patients * No concurrent participation in another investigational study

Locations (1)

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.